Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Free Report)’s share price was up 4.5% during mid-day trading on Friday . The company traded as high as $0.19 and last traded at $0.19. Approximately 405,849 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 2,778,205 shares. The stock had previously closed at $0.18.
Eterna Therapeutics Stock Up 4.5 %
The stock has a market cap of $1.02 million, a price-to-earnings ratio of -0.02 and a beta of 4.79. The company has a 50 day simple moving average of $0.29 and a 200 day simple moving average of $0.56.
Institutional Trading of Eterna Therapeutics
A hedge fund recently raised its stake in Eterna Therapeutics stock. Geode Capital Management LLC raised its holdings in Eterna Therapeutics Inc. (NASDAQ:ERNA – Free Report) by 1,159.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 257,310 shares of the company’s stock after acquiring an additional 236,875 shares during the quarter. Geode Capital Management LLC owned approximately 4.76% of Eterna Therapeutics worth $76,000 as of its most recent SEC filing. 70.55% of the stock is currently owned by institutional investors.
About Eterna Therapeutics
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Featured Stories
- Five stocks we like better than Eterna Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
- What Are Earnings Reports?
- Disney 2025 Shareholders: Major Updates for Investors
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Advance Auto Parts Stock: A Classic Rebound Play in the Making
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.